|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HIST2H2AC |
Gene summary for HIST2H2AC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HIST2H2AC | Gene ID | 8338 |
| Gene name | H2A clustered histone 20 | |
| Gene Alias | H2A | |
| Cytomap | 1q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q16777 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8338 | HIST2H2AC | P27T-E | Human | Esophagus | ESCC | 5.56e-12 | 1.78e-01 | 0.1055 |
| 8338 | HIST2H2AC | P28T-E | Human | Esophagus | ESCC | 7.44e-08 | 1.22e-01 | 0.1149 |
| 8338 | HIST2H2AC | P30T-E | Human | Esophagus | ESCC | 9.72e-07 | 3.22e-01 | 0.137 |
| 8338 | HIST2H2AC | P31T-E | Human | Esophagus | ESCC | 4.73e-06 | 1.40e-01 | 0.1251 |
| 8338 | HIST2H2AC | P32T-E | Human | Esophagus | ESCC | 9.79e-11 | 2.19e-01 | 0.1666 |
| 8338 | HIST2H2AC | P36T-E | Human | Esophagus | ESCC | 2.03e-05 | 2.80e-01 | 0.1187 |
| 8338 | HIST2H2AC | P39T-E | Human | Esophagus | ESCC | 5.39e-05 | 1.09e-01 | 0.0894 |
| 8338 | HIST2H2AC | P40T-E | Human | Esophagus | ESCC | 1.07e-02 | 8.88e-02 | 0.109 |
| 8338 | HIST2H2AC | P42T-E | Human | Esophagus | ESCC | 2.06e-07 | 1.56e-01 | 0.1175 |
| 8338 | HIST2H2AC | P44T-E | Human | Esophagus | ESCC | 3.53e-02 | 1.34e-01 | 0.1096 |
| 8338 | HIST2H2AC | P48T-E | Human | Esophagus | ESCC | 6.17e-05 | 9.15e-02 | 0.0959 |
| 8338 | HIST2H2AC | P49T-E | Human | Esophagus | ESCC | 3.85e-06 | 4.42e-01 | 0.1768 |
| 8338 | HIST2H2AC | P52T-E | Human | Esophagus | ESCC | 1.37e-10 | 2.94e-01 | 0.1555 |
| 8338 | HIST2H2AC | P54T-E | Human | Esophagus | ESCC | 4.28e-05 | 1.56e-01 | 0.0975 |
| 8338 | HIST2H2AC | P57T-E | Human | Esophagus | ESCC | 2.07e-06 | 1.28e-01 | 0.0926 |
| 8338 | HIST2H2AC | P61T-E | Human | Esophagus | ESCC | 4.87e-08 | 1.96e-01 | 0.099 |
| 8338 | HIST2H2AC | P62T-E | Human | Esophagus | ESCC | 5.18e-10 | 2.12e-01 | 0.1302 |
| 8338 | HIST2H2AC | P65T-E | Human | Esophagus | ESCC | 2.99e-07 | 1.04e-01 | 0.0978 |
| 8338 | HIST2H2AC | P74T-E | Human | Esophagus | ESCC | 4.12e-11 | 2.45e-01 | 0.1479 |
| 8338 | HIST2H2AC | P75T-E | Human | Esophagus | ESCC | 1.49e-14 | 3.41e-01 | 0.1125 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HIST2H2AC | SNV | Missense_Mutation | c.287N>T | p.Lys96Met | p.K96M | Q16777 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.925) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| HIST2H2AC | insertion | Frame_Shift_Ins | novel | c.344_345insTCTG | p.Leu117SerfsTer? | p.L117Sfs*? | Q16777 | protein_coding | TCGA-AN-A0G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| HIST2H2AC | SNV | Missense_Mutation | novel | c.89G>C | p.Arg30Pro | p.R30P | Q16777 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| HIST2H2AC | SNV | Missense_Mutation | novel | c.89N>C | p.Arg30Pro | p.R30P | Q16777 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-Q1-A6DT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| HIST2H2AC | SNV | Missense_Mutation | c.304N>G | p.Thr102Ala | p.T102A | Q16777 | protein_coding | deleterious_low_confidence(0.01) | benign(0.249) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| HIST2H2AC | SNV | Missense_Mutation | novel | c.58N>C | p.Ser20Pro | p.S20P | Q16777 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.98) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| HIST2H2AC | SNV | Missense_Mutation | c.230C>T | p.Thr77Met | p.T77M | Q16777 | protein_coding | tolerated_low_confidence(0.08) | probably_damaging(0.927) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| HIST2H2AC | SNV | Missense_Mutation | c.229A>G | p.Thr77Ala | p.T77A | Q16777 | protein_coding | deleterious_low_confidence(0.04) | benign(0.003) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| HIST2H2AC | insertion | Frame_Shift_Ins | novel | c.388_389insA | p.Ter130%3D | p.*130%3D | Q16777 | protein_coding | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR | ||
| HIST2H2AC | deletion | Frame_Shift_Del | c.298_299delNN | p.Lys100SerfsTer11 | p.K100Sfs*11 | Q16777 | protein_coding | TCGA-AG-3881-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |